Respiratory therapy

Global $3.67B Smart Inhalers Market, 2026: Key Industry Insights & Projections - ResearchAndMarkets.com

Retrieved on: 
Monday, April 8, 2019
Health, Medical devices, Pharmaceutical, Dosage forms, Medicine, Health, Asthma, Respiratory therapy, Inhaler, Metered-dose inhaler, Medical terminology, Chronic condition, Respiratory disease, Dry-powder inhaler

According to the research findings of the World Health Organization (WHO), chronic obstructive pulmonary disease is responsible for 5% of global deaths annually.

Key Points: 
  • According to the research findings of the World Health Organization (WHO), chronic obstructive pulmonary disease is responsible for 5% of global deaths annually.
  • Metered dose inhalers (MDIs) are reigning the type segment for smart inhalers market.
  • Chronic obstructive pulmonary disease is currently leading the application segment for smart inhalers market.
  • In the present scenario, North America with a share of 38% is leading the regional segment for smart inhalers market.

Global Hyperbaric Oxygen Therapy (HBOT) Devices Market 2019-2024: Widening Application of HBOT Devices in Cosmetic Procedures and Wound Healing

Retrieved on: 
Wednesday, April 3, 2019
Medicine, Clinical medicine, Chemistry, Diving medicine, Oxygen, Industrial gases, Respiratory therapy, Medical equipment, Hyperbaric medicine, Oxygen therapy, Therapy, Chronic wound

DUBLIN, April 3, 2019 /PRNewswire/ -- The "Hyperbaric Oxygen Therapy (HBOT) Devices Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 3, 2019 /PRNewswire/ -- The "Hyperbaric Oxygen Therapy (HBOT) Devices Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
  • The hyperbaric oxygen therapy (HBOT) devices market is majorly driven by the rising prevalence of acute and chronic wounds, widening the application of HBOT devices in cosmetic procedures and wound healing, and technological advancements.
  • All of the aforementioned factors are expected to propel the growth of the hyperbaric oxygen therapy (HBOT) devices market.
  • The hyperbaric oxygen therapy (HBOT) devices market is moderately competitive and consists of several major players.

D R Burton Healthcare Receives Innovative Technology Contract from Vizient for the J-Wand® Intubating Stylet

Retrieved on: 
Wednesday, April 3, 2019
Respiratory therapist, Respiratory therapy

FARMVILLE, N.C., April 03, 2019 /PRNewswire-PRWeb/ --D R Burton Healthcare announced its J-Wand Semi-Rigid Intubating Stylet has received an Innovative Technology contract from Vizient, Inc. the largest member-driven health care performance improvement company in the country.

Key Points: 
  • FARMVILLE, N.C., April 03, 2019 /PRNewswire-PRWeb/ --D R Burton Healthcare announced its J-Wand Semi-Rigid Intubating Stylet has received an Innovative Technology contract from Vizient, Inc. the largest member-driven health care performance improvement company in the country.
  • He adds, "D R Burton is pleased to receive the Vizient Innovative Technology Contract which offers enhanced savings for the J-Wand stylet."
  • Through its Innovative Technology Program, Vizient works with member-led councils and task forces to review potentially innovative products.
  • D R Burton Healthcare Products LLC, innovators in medical devices, was founded by clinicians with deep expertise in anesthesia and respiratory care.

Inogen Releases Innovative Inogen One G5™ Portable Oxygen Concentrator

Retrieved on: 
Wednesday, April 3, 2019
Health, Medical devices, Medical Supplies, Medicine, Oxygen, Clinical medicine, Respiratory therapy, Health, Industrial gases, Diving medicine, Oxygen therapy, RTT, Forward-looking statement, G5

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning Inogens expectations for market acceptance of its Inogen One G5, the ability of the Inogen One G5 to meet the clinical needs of patients, Inogens belief that the Inogen One G5 can change and improve the lives of patients, and the expected timing and distribution channels for the rollout of the Inogen One G5.

Key Points: 
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning Inogens expectations for market acceptance of its Inogen One G5, the ability of the Inogen One G5 to meet the clinical needs of patients, Inogens belief that the Inogen One G5 can change and improve the lives of patients, and the expected timing and distribution channels for the rollout of the Inogen One G5.
  • Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.
  • Inogen is innovation in oxygen therapy.
  • We are a medical technology company that develops, manufactures and markets innovative oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Insmed To Showcase New ARIKAYCE® (amikacin liposome inhalation suspension) And Pipeline Data At American Thoracic Society International Conference

Retrieved on: 
Monday, April 1, 2019
Dosage forms, Aerosols, Health, Medical equipment, Respiratory therapy, Nebulizer, Liposome, Aerosolization

Additional data on ARIKAYCE as well as on Insmed's pipeline candidates will also be presented at the meeting.

Key Points: 
  • Additional data on ARIKAYCE as well as on Insmed's pipeline candidates will also be presented at the meeting.
  • The course of treatment is often two years or more and is inadequate in treating the disease in many patients.
  • ARIKAYCE(amikacin liposome inhalation suspension)is delivered by a novel inhalation device, the LamiraNebulizer System, developed by PARI.
  • Lamirais a quiet, portable nebulizer that enables efficient aerosolization of liquid medications, including liposomal formulations such as ARIKAYCE, via a vibrating, perforated membrane.

Hyperbaric Oxygen Therapy (HBOT) Devices Market - Global Growth, Trends, and Forecasts 2019-2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 1, 2019
Health, Medical devices, Medicine, Clinical medicine, Chemistry, Diving medicine, Oxygen, Industrial gases, Respiratory therapy, Medical equipment, Hyperbaric medicine, Oxygen therapy, Therapy, Chronic wound

The "Hyperbaric Oxygen Therapy (HBOT) Devices Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hyperbaric Oxygen Therapy (HBOT) Devices Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
  • The hyperbaric oxygen therapy (HBOT) devices market is majorly driven by the rising prevalence of acute and chronic wounds, widening the application of HBOT devices in cosmetic procedures and wound healing, and technological advancements.
  • All of the aforementioned factors are expected to propel the growth of the hyperbaric oxygen therapy (HBOT) devices market.
  • The hyperbaric oxygen therapy (HBOT) devices market is moderately competitive and consists of several major players.

Europe Anesthesia, Respiratory and Sleep Management Device Market Report 2018-2024 Featuring Philips, ResMed, Teleflex, Medtronic, Drger & GE Healthcare

Retrieved on: 
Thursday, March 28, 2019
Medicine, Health, Respiratory therapy, Sleep disorders, Medical equipment, RTT, Sleep apnea, Nebulizer, Medical ventilator, Respiratory therapist

DUBLIN, March 28, 2019 /PRNewswire/ -- The "Anesthesia, Respiratory and Sleep Management Device Market - Europe - 2018-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 28, 2019 /PRNewswire/ -- The "Anesthesia, Respiratory and Sleep Management Device Market - Europe - 2018-2024" report has been added to ResearchAndMarkets.com's offering.
  • Most anesthesia, respiratory and sleep management device market segments are expected to grow at stable rates.
  • With therapeutic sleep management devices accounting for just under half of the overall value in the anesthesia, respiratory and sleep management device market, slight growth in this segment is driving overall market growth.
  • The European market for anesthesia, respiratory, and sleep management (ARS) devices includes anesthesia delivery units, anesthesia disposables, ventilators, nebulizers, respiratory disposable devices, oxygen therapy, sleep apnea devices and interfaces, and sleep diagnostic equipment.

Global Anesthesia, Respiratory and Sleep Management Device Markets 2019: Anesthesia Disposables, Delivery Units and Monitors, Along with the Nebulizer and Ventilator Markets are Saturated

Retrieved on: 
Wednesday, March 27, 2019
Medicine, Health, Clinical medicine, Respiratory therapy, Sleep disorders, RTT, Medical equipment, Sleep apnea, Nebulizer, Obstructive sleep apnea, Anesthesia, Medical ventilator

DUBLIN, March 27, 2019 /PRNewswire/ -- The "Anesthesia, Respiratory and Sleep Management Device Market Report Suite - United States - 2019-2025 (Includes 11 Reports)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 27, 2019 /PRNewswire/ -- The "Anesthesia, Respiratory and Sleep Management Device Market Report Suite - United States - 2019-2025 (Includes 11 Reports)" report has been added to ResearchAndMarkets.com's offering.
  • The markets for anesthesia disposables, delivery units and monitors, along with the nebulizer and ventilator markets, are set to demonstrate lower levels of growth than other sectors.
  • On the other hand, the markets for therapeutic sleep management devices and oxygen therapy devices are set to grow over the forecast period.
  • This anesthesia, respiratory and sleep apnea market includes analysis for anesthesia delivery units (ADUs), anesthesia patient monitors, anesthesia information management systems (AIMS), anesthesia disposables, ventilators, nebulizers, respiratory disposables, oxygen therapy devices, therapeutic obstructive sleep apnea (sleep therapy) devices and sleep diagnostic devices.

In Comparison of Standard Treatment and Sustained Inflations for Extremely Preterm Infants, Standard Treatment Prevails

Retrieved on: 
Tuesday, March 26, 2019
Medical specialties, Medicine, Health, Neonatology, Respiratory therapy, Intensive care medicine, Mechanical ventilation, Infancy, Preterm birth, Bronchopulmonary dysplasia, Modes of mechanical ventilation

Pooled data from smaller randomized trials were conflicting: one showed that sustained inflations reduced the need for mechanical ventilation.

Key Points: 
  • Pooled data from smaller randomized trials were conflicting: one showed that sustained inflations reduced the need for mechanical ventilation.
  • In infants younger than 30 weeks gestational age, sustained inflations are commonly used in delivery rooms in Europe, but not in the United States.
  • This was possible using sustained inflations at delivery, as these appeared beneficial in animal models, and in smaller prior human studies.
  • Effect of Sustained Inflations vs Intermittent Positive Pressure Ventilation on Bronchopulmonary Dysplasia or Death Among Extremely Preterm Infants: The SAIL Randomized Clinical Trial.

Emergency Department Subgroup Study Showed Hi-VNI® Technology Had Similar Outcomes to Non-invasive Positive Pressure Ventilation in Management of Respiratory Distress Among Acute Decompensated Heart Failure Patients

Retrieved on: 
Tuesday, March 26, 2019
Health, Biotechnology, Cardiology, Medical devices, Other Health, General Health, Medical specialties, Medicine, Health care, Intensive care medicine, Mechanical ventilation, Respiratory therapy, Emergency medicine, Shortness of breath, Hypoxemia, Respiratory arrest

This analysis shows that even if that diagnosis is respiratory distress due to exacerbation of CHF, Hi-VNI Technology provides Mask-Free NIV for spontaneously breathing patients and is potentially a viable alternative to NiPPV.

Key Points: 
  • This analysis shows that even if that diagnosis is respiratory distress due to exacerbation of CHF, Hi-VNI Technology provides Mask-Free NIV for spontaneously breathing patients and is potentially a viable alternative to NiPPV.
  • This is particularly important for ED clinicians who may need to make treatment decisions before knowing the patient diagnosis.
  • Vapotherm, Inc.(NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA.
  • Hi-VNI Technologyis mask-free noninvasive ventilation for spontaneously breathing patients and a front-line tool for relieving respiratory distressincluding hypercapnia, hypoxemia, and dyspnea.